Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
Open Access
- 1 November 2019
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 30 (Suppl_8), viii36-viii40
- https://doi.org/10.1093/annonc/mdz385
Abstract
Background: Although rare, NTRK gene fusions are known to be oncogenic drivers in pancreatic ductal adenocarcinoma (PDAC). We report the response of a metastatic CTRC-NTRK1 gene fusion-positive PDAC to targeted treatment with the oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib and the eventual development of resistance to treatment. Patient, methods and results: A 61-year-old woman presented with a 2.5-cm mass in the body of the pancreas and a 1.2-cm liver lesion on routine follow-up for endometrial cancer that was in complete remission. Liver biopsy confirmed a primary PDAC unrelated to the endometrial cancer. The patient was treated with gemcitabine, nab-paclitaxel and ADI-PEG 20 for 12 months until disease progression and toxicity emerged [best overall response (BOR): partial response (PR)]. The patient switched to a modified regimen of folinic acid, fluorouracil, irinotecan and oxaliplatin for 4 months until neuropathy occurred. Oxaliplatin was withheld until disease progression 6 months later (BOR: stable disease). Despite recommencing oxaliplatin, the disease continued to progress. At this time, somatic profiling of the liver lesion revealed a CTRC-NTRK1 gene fusion. Treatment with larotrectinib 100 mg twice daily was commenced with BOR of PR at 2 months. The patient progressed after 6 months and was re-biopsied. Treatment was switched to the investigational next-generation TRK inhibitor selitrectinib (BAY 2731954, LOXO-195) 100 mg twice daily. After 2 months, the disease progressed and dabrafenibtrametinib combination therapy was initiated due to existence of a BRAF-V600E mutation. However, the cancer continued to progress and the patient died 2 months later. Conclusions: Targeted TRK inhibition with larotrectinib in PDAC harbouring a CTRC-NTRK1 gene fusion is well tolerated and can improve quality of life for the patient. However, acquired resistance to therapy can emerge in some patients. Next-generation TRK inhibitors such as selitrectinib are currently in development to overcome this resistance.Funding Information
- National Institutes of Health (NIH P30-CA008748)
- David M. Rubenstein Center for Pancreatic Cancer Research
- Bayer AG and Loxo Oncology, Inc.
This publication has 13 references indexed in Scilit:
- NTRK fusion-positive cancers and TRK inhibitor therapyNature Reviews Clinical Oncology, 2018
- TRK Inhibition: A New Tumor-Agnostic Treatment StrategyTargeted Oncology, 2018
- Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?Clinical Cancer Research, 2018
- Efficacy of Larotrectinib inTRKFusion–Positive Cancers in Adults and ChildrenThe New England Journal of Medicine, 2018
- Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategiesCancer Treatment Reviews, 2017
- Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing DataJCO Precision Oncology, 2017
- A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid TumorsCancer Discovery, 2017
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsNature Medicine, 2017
- Abstract C65: TRK kinase domain mutations that induce resistance to a pan-TRK inhibitorMolecular Cancer Therapeutics, 2015
- TRKing Down an Old Oncogene in a New Era of Targeted TherapyCancer Discovery, 2015